Obesity and Diabetes Research As a multi-receptor agonist, Retatrutide is being investigated for its potential to improve glycemic control and reduce body weight, making it valuable for preclinical studies related to obesity and type 2 diabetes
Retatrutide is a triple-receptor agonist peptide that targets GLP-1, GIP, and glucagon receptors simultaneously
"There are GLP-1 receptors in the heart, and so these cardiovascular effects are probably[due to] a combination of weight loss and indirect effects on the heart," Dr
But the guidelines for oral sublingual preparations are less clear
Reduced Cardiovascular Risk: By promoting weight loss and improving metabolic profiles (blood glucose, cholesterol), Retatrutide can reduce the risk of cardiovascular diseases, which are often linked to obesity and diabetes
Appetite changes: Hunger pangs became "extremely ignorable and in the background." Reduced from normal eating patterns to roughly two meals daily
